Brazil IVD disclosure repeal bodes well for medtech-wide challenge
This article was originally published in Clinica
Brazil’s IVD industry association, the national chamber for laboratory diagnostics (CBDL), has secured an exemption from a new requirement on importers to disclose sensitive commercial information. The victory for CBDL members bodes well for the rest of the medical technology industry: Abimed, the leading medtech importers association, is challenging the requirement at state authority level in eight key states (www.clinica.co.uk, 21 May 2013).
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.